Bigbear Pharmaceutical·Medication Guide

• What Is Apalutamide Used For

  Apalutamide is an oral anti-androgen medication, mainly used to treat non-metastatic or metastatic castration-resistant prostate cancer. It delays tum···【Read More】

  Update: 2026-03-04Source: Haiou HealthViews: 126

• FDA Approves Erleada (apalutamide) for Non-Metastatic Castration-Resistant Prostate Cancer

  FDA Approval AnnouncementFebruary 14, 2018 -- The U.S. Food and Drug Administration today approved Erleada (apalutamide) for the treatment of patients···【Read More】

  Update: 2026-03-04Source: Haiou HealthViews: 123

• FDA Approves Erleada (apalutamide) for the Treatment of Patients with Metastatic Castration-Sensitiv

  FDA Approval AnnouncementHORSHAM, Pa., Sept. 17, 2019 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today th···【Read More】

  Update: 2026-03-04Source: Haiou HealthViews: 119

• Sotorasib (Lumakras) Patient Guide: How It Works, Side Effects, and Dosing Tips

  KRAS mutations have been considered a major challenge in cancer research, remaining difficult to overcome for many years. The introduction of Sotorasi···【Read More】

  Update: 2026-03-04Source: Haiou HealthViews: 120

• Sotorasib (Lumakras) Explained: Uses, Effectiveness, and What to Expect

  Sotorasib is a KRASG12C inhibitor developed by Amgen. It received accelerated approval from the U.S. Food and Drug Administration (FDA) in May 2021.I.···【Read More】

  Update: 2026-03-03Source: Haiou HealthViews: 121

• Common Sotorasib Side Effects and How to Manage Them: A Patient’s Guide

  In 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to sotorasib for the treatment of certain adult patients with non-sm···【Read More】

  Update: 2026-03-03Source: Haiou HealthViews: 124

• Sotorasib (Lumakras) Dosage Guide: How to Take It Safely for NSCLC and mCRC

  Sotorasib is an oral targeted anticancer drug developed by Amgen, a small molecule inhibitor specifically targeting the KRAS G12C mutation.Indications···【Read More】

  Update: 2026-03-03Source: Haiou HealthViews: 128

• New Sabril (Vigabatrin) Pediatric Formulation Shows Promise for Infantile Spasms in 2026 Clinical Tr

  On June 13, 2024, Bristol-Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to repotrectinib fo···【Read More】

  Update: 2026-03-03Source: Haiou HealthViews: 106

• Sabril for Infantile Spasms (West Syndrome): A Complete Guide for Parents

  On November 16, 2023, Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has approved ripretinib (Augtyro) for the treatm···【Read More】

  Update: 2026-03-03Source: Haiou HealthViews: 128

• Understanding the Sabril (Vigabatrin) Black Box Warning: Risk of Permanent Vision Loss

  Ripretinib (Augtyro) is a next-generation targeted anticancer drug developed by Bristol-Myers Squibb (BMS), offering a new precision treatment option ···【Read More】

  Update: 2026-03-03Source: Haiou HealthViews: 110

• Sabril Side Effects: What to Expect and When to Call Your Doctor Immediately

  Repotrectinib is a novel, oral, small-molecule, multi-target tyrosine kinase inhibitor (TKI) primarily used to treat advanced solid tumors harboring s···【Read More】

  Update: 2026-03-03Source: Haiou HealthViews: 123

• Sabril (Vigabatrin) Dosage Guide: What is the Typical Starting Dose for Adults and Children?

  Repotrectinib, an innovative ROS1 and NTRK-targeting inhibitor, can simultaneously inhibit multiple oncogenic targets, exhibiting broad-spectrum anti-···【Read More】

  Update: 2026-03-03Source: Haiou HealthViews: 116

• Side effects of Repotrectinib: serious adverse reactions, common side effects

  Repotrectinib is a new generation of targeted anticancer drug developed by Bristol-Myers Squibb (BMS), providing a new option for precision treatment ···【Read More】

  Update: 2026-03-03Source: Haiou HealthViews: 123

• Indications for Cabozantinib (Cabometyx)

  Cabozantinib (Cabometyx), first approved by the FDA in 2012, is a non-specific tyrosine kinase inhibitor. It exerts its anti-tumor effect by targeting···【Read More】

  Update: 2026-03-03Source: Haiou HealthViews: 128

• Official Market Price of Bedaquiline

  Bedaquiline is a diarylquinoline anti-mycobacterial drug, which requires a prescription from a qualified physician and full medical supervision. It mu···【Read More】

  Update: 2026-03-03Source: Haiou HealthViews: 123